Presentation | January 9, 2014

BIOSIMILARS--Global Terminology, Strategy & Pathways

Source: Baxter

Features Baxter's Kelly Davis, Regulatory Affairs, Associate Director, and outlines:

  • Biosimilar definition
  • US and Europe Regulatory Pathways
  • Biologics Price Competition and Innovation Act
  • 351(k) Application Requirements
access the Presentation!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.

Subscribe to Outsourced Pharma X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Outsourced Pharma

Please tell us more about you so that we can customize our newsletters to your specific interests:

What topics interest you? (Check all that apply.)